Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOMAC-E2 combined oral contraceptive in premenopausal females
NCT05264506Phase 3Terminated
- Sponsor
- Organon & Co.
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nesvategrast, sponsored by Organon & Co. Primary endpoint: Number of Participants With On-treatment Pregnancies at 1 year. Started Feb 2022; status: terminated.
02
Drugs
nesvategrast
Beyond the preview
Go deeper on NCT05264506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264506.